» Articles » PMID: 22672351

Emergence of Biopharmaceutical Innovators in China, India, Brazil, and South Africa As Global Competitors and Collaborators

Overview
Publisher Biomed Central
Date 2012 Jun 8
PMID 22672351
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Biopharmaceutical innovation has had a profound health and economic impact globally. Developed countries have traditionally been the source of most innovations as well as the destination for the resulting economic and health benefits. As a result, most prior research on this sector has focused on developed countries. This paper seeks to fill the gap in research on emerging markets by analyzing factors that influence innovative activity in the indigenous biopharmaceutical sectors of China, India, Brazil, and South Africa. Using qualitative research methodologies, this paper a) shows how biopharmaceutical innovation is taking place within the entrepreneurial sectors of these emerging markets, b) identifies common challenges that indigenous entrepreneurs face, c) highlights the key role played by the state, and d) reveals that the transition to innovation by companies in the emerging markets is characterized by increased global integration. It suggests that biopharmaceutical innovators in emerging markets are capitalizing on opportunities to participate in the drug development value chain and thus developing capabilities and relationships for competing globally both with and against established companies headquartered in developed countries.

Citing Articles

Climate change and the sustainable use of medicinal plants: a call for "new" research strategies.

Mykhailenko O, Jalil B, McGaw L, Echeverria J, Takubessi M, Heinrich M Front Pharmacol. 2025; 15:1496792.

PMID: 39963365 PMC: 11830725. DOI: 10.3389/fphar.2024.1496792.


Rising pharmaceutical innovation in the Global South: a landscape study.

Vieira M, Andia T, Karim O, Srishti S, Pineda S, Ruiz A J Pharm Policy Pract. 2023; 16(1):155.

PMID: 38012700 PMC: 10680326. DOI: 10.1186/s40545-023-00669-3.


Indian Biosimilars and Vaccines at Crossroads-Replicating the Success of Pharmagenerics.

Panda S, Singh P, Mishra S, Mitra S, Pattnaik P, Adhikary S Vaccines (Basel). 2023; 11(1).

PMID: 36679955 PMC: 9865573. DOI: 10.3390/vaccines11010110.


Localizing pharmaceuticals manufacturing and its impact on drug security in Saudi Arabia.

Tawfik E, Tawfik A, Alajmi A, Badr M, Al-Jedai A, Almozain N Saudi Pharm J. 2022; 30(1):28-38.

PMID: 35145343 PMC: 8802089. DOI: 10.1016/j.jsps.2021.12.002.


Research capacity of global health institutions in China: a gap analysis focusing on their collaboration with other low-income and middle-income countries.

Kwete X, Tang K, Cheng F, Chen Y, Hao Y, Mao Z BMJ Glob Health. 2021; 6(7).

PMID: 34266847 PMC: 8286742. DOI: 10.1136/bmjgh-2021-005607.


References
1.
Trouiller P, Olliaro P, Torreele E, Orbinski J, Laing R, Ford N . Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet. 2002; 359(9324):2188-94. DOI: 10.1016/S0140-6736(02)09096-7. View

2.
Frew S, Sammut S, Shore A, Ramjist J, Al-Bader S, Rezaie R . Chinese health biotech and the billion-patient market. Nat Biotechnol. 2008; 26(1):37-53. PMC: 7096943. DOI: 10.1038/nbt0108-37. View

3.
Zhang Y, Deng M . Enforcing pharmaceutical and biotech patent rights in China. Nat Biotechnol. 2008; 26(11):1235-40. DOI: 10.1038/nbt1108-1235. View

4.
Al-Bader S, Frew S, Essajee I, Liu V, Daar A, Singer P . Small but tenacious: South Africa's health biotech sector. Nat Biotechnol. 2009; 27(5):427-45. DOI: 10.1038/nbt0509-427. View

5.
Frew S, Rezaie R, Sammut S, Ray M, Daar A, Singer P . India's health biotech sector at a crossroads. Nat Biotechnol. 2007; 25(4):403-17. DOI: 10.1038/nbt0407-403. View